MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hood, W. F.
Right arrow Articles by Monahan, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hood, W. F.
Right arrow Articles by Monahan, J. B.

Vol. 63, Issue 4, 870-877, April 2003

Characterization of Celecoxib and Valdecoxib Binding to Cyclooxygenase

William F. Hood, James K. Gierse, Peter C. Isakson, James R. Kiefer, Ravi G. Kurumbail, Karen Seibert, and Joseph B. Monahan

Pharmacia Research and Development, St. Louis, Missouri

Two compounds (celecoxib and valdecoxib) from the diarylheterocycle class of cyclooxygenase inhibitors were radiolabeled and used to characterize their binding to cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), several single-point variants of COX-2 (Val523Ile, Tyr355Ala, Arg120Ala, Arg120Gln, Arg120Asn) and one triple-point variant of COX-2 [Val523Ile, Arg513His, Val434Ile (IHI)]. We demonstrate highly specific and saturable binding of these inhibitors to COX-2. Under the same assay conditions, little or no specific binding to COX-1 could be detected. The affinity of [3H]celecoxib for COX-2 (KD = 2.3 nM) was similar to the affinity of [3H]valdecoxib (KD = 3.2 nM). The binding to COX-2 seems to be both rapid and slowly reversible with association rates of 5.8 × 106/M/min and 4.5 × 106/M/min and dissociation rates of 14 × 10-3/min (t1/2 = 50 min) and 7.0 × 10-3/min (t1/2 = 98 min) for [3H]celecoxib and [3H]valdecoxib, respectively. These association rates increased (4- to 11-fold) when the charged arginine residue located at the entrance to the main hydrophobic channel was mutated to smaller uncharged amino acids (Arg120Ala, Arg120Gln, and Arg120Asn). Mutation of residues located within the active site of COX-2 that define a `side pocket' (Tyr355Ala, Val523Ile, IHI) of the main channel had a greater effect on the dissociation rate than the association rate. These mutations, which modified the shape of and access to the `side pocket', affected the binding affinity of [3H]valdecoxib more than that of [3H]celecoxib. These binding studies provide direct insight into the properties and binding constants of celecoxib and valdecoxib to COX-2.

Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
S. Takeda, K. Misawa, I. Yamamoto, and K. Watanabe
Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis
Drug Metab. Dispos., September 1, 2008; 36(9): 1917 - 1921.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. L. Julius, O. K. Farha, J. Chiang, L. J. Perry, and M. F. Hawthorne
Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores
PNAS, March 20, 2007; 104(12): 4808 - 4813.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. Lev-Ari, L. Strier, D. Kazanov, O. Elkayam, D. Lichtenberg, D. Caspi, and N. Arber
Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells
Rheumatology, February 1, 2006; 45(2): 171 - 177.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Lev-Ari, L. Strier, D. Kazanov, L. Madar-Shapiro, H. Dvory-Sobol, I. Pinchuk, B. Marian, D. Lichtenberg, and N. Arber
Celecoxib and Curcumin Synergistically Inhibit the Growth of Colorectal Cancer Cells
Clin. Cancer Res., September 15, 2005; 11(18): 6738 - 6744.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. K. Gierse, Y. Zhang, W. F. Hood, M. C. Walker, J. S. Trigg, T. J. Maziasz, C. M. Koboldt, J. L. Muhammad, B. S. Zweifel, J. L. Masferrer, et al.
Valdecoxib: Assessment of Cyclooxygenase-2 Potency and Selectivity
J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1206 - 1212.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Bingham, P. J. Beswick, C. Bountra, T. Brown, I. B. Campbell, I. P. Chessell, N. Clayton, S. D. Collins, P. T. Davey, H. Goodland, et al.
The Cyclooxygenase-2 Inhibitor GW406381X [2-(4-Ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] Is Effective in Animal Models of Neuropathic Pain and Central Sensitization
J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1161 - 1169.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
Y. Birnbaum, Y. Ye, S. Rosanio, S. Tavackoli, Z.-Y. Hu, E. R. Schwarz, and B. F. Uretsky
Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury
Cardiovasc Res, February 1, 2005; 65(2): 345 - 355.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics